Enpicom has introduced two apps for its ImmunoGenomiX (IGX) platform featuring the antibody discovery module (ADM). The platform is designed to allow scientists in biopharmaceutical companies and academia, as well as service providers working in the antibody discovery field, to make the most of their Sanger and NGS data and independently perform complex analyses.
Data integration, analysis, and visualization can be challenging and require diverse expertise, including immunology, protein biology, and bioinformatics. In collaboration with more than 50 industry peers, Enpicom has identified bottlenecks and challenges in the antibody discovery process and designed the platform to help solve these. The company has introduced a set of IGX Platform Apps engineered to identify a diverse set of promising antibody candidates from integrated sequencing data.
"By conducting thorough interviews with a large group of industry leaders, we gained a deep understanding of the specific pain points and needs in the market." explained Jos Lunenberg, co-founder and CEO at Enpicom. "We learned exactly what researchers need, and as a result, can offer something truly unique: a validated solution, tailored to the specific needs of antibody developers. This allows researchers without extensive bioinformatics expertise to independently perform their discovery analysis and stay focused on what matters the most – their research."
"Extensive product discovery efforts have led to the identification of several new analyses and data management features that are key to the workflow of antibody developers." commented Nicola Bonzanni, co-founder and Chief Product Officer at ENPICOM. "With our new module built on top of the powerful IGX Platform core, we empower scientists to discover and perform in-depth analysis on drug candidate sequences in the context of therapeutic antibody development."
The two apps developed for the ADM release are IGX-Cluster and IGX-Branch. Cluster groups sequences based on user-defined parameters such as CDR3 similarity, gene usage, and CDR3 length. It performs clustering tasks in the cloud and supports various workflows for both paired and unpaired receptor chains. Subsequently, Branch creates interactive visualisations to prioritise clusters and pick antibody candidates for follow-up analysis through phylogenetic trees.
The platform is marketed as a tool to manage, analyse, integrate, and visualise immune repertoire sequencing data in a single environment. With the two apps, it provides a setup for tasks like candidate selection and hit expansion, aiming to create a versatile system to discover promising antibody candidates.
Other features released today include revamped receptor profiling workflows and improved metadata importing.
